Protocol for Herceptin as Adjuvant Therapy With Reduced Exposure to Chemotherapy (PHARE-C)
Status: NOT_YET_RECRUITING
Study type: INTERVENTIONAL
Conditions: HER2-positive Breast Cancer
Interventions: DRUG: Paclitaxel + Trastuzumab|DRUG: Trastuzumab
Sponsor: Institut de cancérologie Strasbourg Europe